The present invention relates to soluble guanylate cyclase (sGC) and tophosphodiesterases (PDEs) and thephar-macology of sGC stimulators, sGC activators and PDE inhibitors. Moreparticularly, the invention relates to the use of sGCstimu-lators and sGC activators in combination with PDE5 inhibitors forpreparation of medicaments for the treatment of male erectiledysfunction (MED) in particular for the MED treatment of difficult to treatpatients and patients not or not fully responding toPDE5 inhibitors.